Sandoz develops and manufactures off-patent generic and biosimilar medicines, making established treatments more affordable and accessible to patients worldwide. The company pioneered biosimilar development in 2006 and now has around 1,500 generics in its portfolio, with its production network supporting more than one billion patient treatments each year. Its history of pharmaceutical innovation reaches back to the first oral penicillin in 1951.